Skyhawk news

Browse:

Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression

July 6, 2022
Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets
Companies to leverage Skyhawk’s proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to...
Read
2 min read
July 6, 2022
Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfront
A heavily financed biotech looking to drug RNA with small molecules is adding yet another company to its Big Pharma shortlist.
Read
3 min read
September 14, 2021
Skyhawk Therapeutics Completes New Investment Round
A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates in
Read
1 min read
September 14, 2021
Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic
A few years after becoming one of the first major biotechs out to drug RNA with small molecules, serial entrepreneur and filmmaker Bill Hane
Read
3 min read
April 13, 2021
Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President
Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President and Graeme Smith PhD as SVP NonClinical Development
Read
2 min read